Publication List
Co-author of over 15, with three as the first author. Below are some of most relevant publications. For a complete list, please refer to my ORCID: 0000-0003-1740-7379.
1. Prevalence of pathogenic germline variants in patients with metastatic renal cell carcinoma. Santos M, et al. Genetics in Medicine. 2021. 10.1038/s41436-020-01062-0
2. PBRM1 and KDM5C cooperate to define high-angiogenesis tumors and increased antiangiogenic response in renal cancer. Santos M, et al. American Journal of Cancer Research. 2023;13(5):2116-2125.
3. Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. Santos M, et al. Genetics in Medicine. 2018; 20(6):622-629.
4. Interrogating the significance of PARP1 expression and PBRM1 mutation as biomarkers for predicting the response to atezolizumab plus bevacizumab or to sunitinib in clear cell renal cell carcinoma patients. Lanillos J, Santos M, et al.
European Urology. 2022.
5. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome. Roldan-Romero JM, Santos M, et al. Modern Pathology. 2020.
6. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma. Roldan-Romero JM, (...), Santos M, et al. International Journal of Cancer. 2020; 146(5):1435-1444.
7. A novel approach for the identification of pharmacogenetic variants in MT-RNR1 through next-generation sequencing off-target data. Lanillos J, Santos M, et al. Journal of Clinical Medicine. 2020; 9(7):E2082.